Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
4/16/2024 | $3.50 | Buy | TD Cowen | |
4/4/2024 | $3.25 | Buy | Jefferies | |
10/5/2023 | $3.50 → $2.29 | Buy → Hold | Jefferies | |
9/25/2023 | $5.00 → $2.50 | Buy → Hold | Canaccord Genuity | |
7/12/2023 | $4.00 | Overweight | KeyBanc Capital Markets | |
2/1/2022 | $12.00 | Buy | Stifel | |
12/14/2021 | $19.00 | Buy | Canaccord Genuity | |
12/10/2021 | $16.00 | Buy | Jefferies |
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti
Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
3 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
S-8 - STANDARD BIOTOOLS INC. (0001162194) (Filer)
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm's fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET. The presentation will be webcast live and available on the Investor Relations page of the Company's website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that its management team will participate in the following investor conferences in the month of August: Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m. ETUBS Genomic Medicine Summit on August 14th, 2024President and CEO, Michael Egholm, PhD, will participate in a panel discussion: Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. PT Available presentations will be webcast live and available on the Investo
Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business Officer SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that Jeffrey Black, Chief Financial Officer, will resign from the Company, effective August 31, 2024, to accept an opportunity at another public company. Alex Kim, the Company's Chief Operating Officer and co-founder of Standard BioTools, will serve as Standard BioTools' interim Chief Financial Officer starting on
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced unaudited interim financial results for the second quarter and six months ended June 30, 2024. "We are laser-focused on optimizing our cost structure, already seeing early integration synerg
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on July 31, 2024, to discuss second quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US c
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced fina
-S-3 https://www.sec.gov/Archives/edgar/data/1162194/000110465924072927/tm2417094-1_s3.htm
The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Marygold Companies The Trade: The Marygold Companies, Inc. (NYSE:MGLD) 10% owner Nicholas & Melinda Gerber Living Trust bought a total of 80,000 shares at an average price of $1.35. To acquire these shares, it cost around $107,760. What's Happ
TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50
Jefferies initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.25
Jefferies downgraded SomaLogic from Buy to Hold and set a new price target of $2.30 from $3.50 previously
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)